{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=43",
    "query": {
      "condition": "Normal Pregnancy",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 1973,
    "total_pages": 198,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T18:49:43.587Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00579514",
      "title": "Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Bladder Cancer",
        "Kidney Cancer",
        "Colon Cancer",
        "Prostate Cancer",
        "Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PCR/PCR/LDR Strategy",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 21081,
      "start_date": "2000-03",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579514"
    },
    {
      "nct_id": "NCT00179816",
      "title": "Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ewing's Sarcoma",
        "Soft Tissue Sarcoma",
        "Hepatoblastoma",
        "Hodgkin's Disease",
        "Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "High-Dose Chemotherapy with Tandem PBSC Rescue.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "1999-04",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2010-10-11",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179816"
    },
    {
      "nct_id": "NCT05132426",
      "title": "Osteopathic Manipulative Treatment for Recurrent Mastitis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mastitis"
      ],
      "interventions": [
        {
          "name": "Osteopathic Manipulative Treatment (OMT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Western University of Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2021-10-29",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "Pomona, California",
      "locations": [
        {
          "city": "Pomona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05132426"
    },
    {
      "nct_id": "NCT03383835",
      "title": "Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Omega-3 Supplementation",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Lauren Nye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 40 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2018-02-05",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-05-23",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "Westwood, Kansas",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03383835"
    },
    {
      "nct_id": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumors",
        "NSCLC",
        "HNSCC",
        "Melanoma",
        "TNBC",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Urothelial Carcinoma",
        "Clear Cell RCC",
        "HCC"
      ],
      "interventions": [
        {
          "name": "Enzelkitug",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2022-10-20",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05581004"
    },
    {
      "nct_id": "NCT04849858",
      "title": "Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fibroids",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Liposomal bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2019-05-20",
      "completion_date": "2023-01-13",
      "has_results": false,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849858"
    },
    {
      "nct_id": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Esophageal Squamous Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IIB Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIC Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Esophageal Carcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Hepatocellular Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Cutaneous Melanoma",
        "Metastatic Esophageal Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Esophageal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unresectable Cutaneous Melanoma",
        "Unresectable Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Home Health Encounter",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Monitoring",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-04-30",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265285"
    },
    {
      "nct_id": "NCT00390091",
      "title": "Study of LJP 394 (Abetimus Sodium) in Lupus Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "abetimus sodium (LJP 394)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "La Jolla Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-09-01",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Duncansville, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00390091"
    },
    {
      "nct_id": "NCT05142033",
      "title": "Avera Cancer Sequencing and Analytics Protocol (ASAP)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Cancer Diagnosis",
        "Early Detection of Cancer",
        "Breast Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "GI Cancer",
        "Gynecologic Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "CNS Cancer",
        "Hematologic Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Avera McKennan Hospital & University Health Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25000,
      "start_date": "2021-11-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 6,
      "location_summary": "Marshall, Minnesota • Aberdeen, South Dakota • Mitchell, South Dakota + 3 more",
      "locations": [
        {
          "city": "Marshall",
          "state": "Minnesota"
        },
        {
          "city": "Aberdeen",
          "state": "South Dakota"
        },
        {
          "city": "Mitchell",
          "state": "South Dakota"
        },
        {
          "city": "Pierre",
          "state": "South Dakota"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142033"
    },
    {
      "nct_id": "NCT07148050",
      "title": "Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor (Excluding CNS)",
        "Liver Cell Carcinoma",
        "Malignant Rhabdoid Tumor",
        "Yolk Sac Tumor",
        "Liposarcoma",
        "Rhabdomyosarcoma",
        "Embryonal Sarcoma of Liver",
        "Wilms Tumor",
        "Hepatocellular Carcinoma",
        "Hepatoblastoma"
      ],
      "interventions": [
        {
          "name": "SC-CAR.GPC3xIL15.21 CAR T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "1 Year to 26 Years"
      },
      "enrollment_count": 21,
      "start_date": "2025-12-22",
      "completion_date": "2044-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-31T18:49:43.587Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07148050"
    }
  ]
}